Anthera Pharma (ANTH) PT Lowered to $1.75 at Jefferies Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Pre-Open Stock Movers 08/10: (HDSN) (GLPG) (PRGO) Higher; (BW) (QTM) (CBI) Lower (more...)
August 10, 2017 9:27 AM EDTToday's Pre-Open Movers
Babcock & Wilcox (NYSE: BW) 29.2% LOWER; reported Q2 EPS of ($2.56), which may not compare to the analyst estimate of $0.06. Revenue for the quarter came in at $349.8 million versus the consensus estimate of $434.34 million.
Quantum Corp. (NYSE: QTM) 22.3% LOWER; reported Q1 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $119.41 million. Quantum Corp. sees FY2018 revenue of $515-525 million, versus the consensus of $528.43... More
After-Hours Stock Movers 08/09: (HDSN) (ASYS) (LYV) Higher; (BW) (QTM) (CBI) Lower (more...)
August 9, 2017 6:01 PM EDTToday's After-Hours Movers
Babcock & Wilcox (NYSE: BW) 29.2% LOWER; reported Q2 EPS of ($2.56), which may not compare to the analyst estimate of $0.06. Revenue for the quarter came in at $349.8 million versus the consensus estimate of $434.34 million.
Quantum Corp. (NYSE: QTM) 22.3% LOWER; reported Q1 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $119.41 million. Quantum Corp. sees FY2018 revenue of $515-525 million, versus the consensus of $528.43 million.
Hudson... More
Anthera Pharma (ANTH) Confirms FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
August 9, 2017 4:01 PM EDTAnthera Pharmaceuticals (Nasdaq: ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A nephropathy (IgAN). Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including IgAN, systemic lupus erythematosus, and others.
We are pleased by the FDAs decision to designate blisibimod with orphan drug designation, said Craig Thompson, Chief Executive Officer of... More
Anthera Pharma's (ANTH) Blisibimod Receives FDA Orphan Drug Status
August 9, 2017 6:25 AM EDTAnthera Pharma' (NASDAQ: ANTH) Blisibimod received FDA orphan drug status for treatment of patients with immunoglobulin A... More
